# AI-DataScience Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ai-datascience-co

- Industry: Software
- Headquarters: Tokyo, Japan
- Website: www.ai-dscience.com/
- Total disclosed funding: $1.7M
- Latest round: Angel (Jan 30, 2024)
- Investors on record: 1

## About

AI-DataScience Co., Ltd., based in Tokyo, Japan, focuses on creating advanced AI-driven SaaS solutions that tackle various societal issues, particularly in healthcare and corporate efficiency.Founded in 2023, AI-DataScience Co., Ltd. provides innovative solutions in the AI and data science sectors. The company is located in Tokyo, Japan, and has completed 2 deals to date. It successfully raised JPY 60 million in Seed funding in May 2025 from individual investors and other unspecified investors. Kazunari Kurahashi serves as the CEO of the company, steering its strategic direction.AI-DataScience Co., Ltd. specializes in developing high-value SaaS solutions that leverage artificial intelligence (AI) and data science to address various societal challenges. Their core offerings include the AI diagnostic assistant, Curalumi, which reduces patient consultation times by up to 50% and enhances diagnostic accuracy through multi-language support, catering to a diverse patient demographic. Another key product is the AI telephone system, Fastmane® Call, designed to optimize call center operations by providing 24/7 support, reducing operational burdens, and improving customer satisfaction. The company actively markets its products in Japan and other Asian markets, with a focus on healthcare facilities, financial institutions, and various corporate sectors seeking to enhance operational efficiency through AI integration.AI-DataScience Co., Ltd. generates revenue through direct business transactions and partnerships. Their primary revenue model includes subscription-based services for their AI solutions, enabling clients to access ongoing support and updates. Additionally, partnerships with healthcare providers and corporate clients often involve revenue-sharing agreements, where clients can sell the products to end-users while sharing a percentage of the earnings with the company. For example, hospitals utilizing Curalumi can implement it as part of their diagnostic processes, enhancing patient throughput while contributing to the firm's revenue through a structured agreement. Such models ensure that both the company and its clients benefit mutually from the deployment of AI technologies.In May 2025, AI-DataScience Co., Ltd. plans to utilize the JPY 60 million raised in Seed funding to advance its medical AI solutions, initiate projects with other industries, hire additional employees, enhance its development systems and security, and invest in product promotion. The company aims to launch new products in the coming years while expanding its reach into additional Asian markets, enhancing its service offerings and market penetration.

## Funding rounds

- Angel, Jan 30, 2024, $1.7M — East Ventures

## Investors

- East Ventures (https://capitalatlas.ai/funds/east-ventures) — Angel